Ligand’s Partnered Drugs for Diabetes / Dyslipidemias

Drug / Receptor Target

Partner

Indication

Status

GW 544 / PPAR

Modulator

Glaxo

Dyslipidemias

Phase I

GW 516 / PPAR

Selective

Glaxo

Dyslipidemias

Phase I

LY 929 / PPAR

Modulator

Lilly

Type II diabetes /

Dyslipidemias

IND Track

LY XXX / PPAR

Modulator

Lilly

Dyslipidemias

Dev Track

LY 818 / PPAR

Modulator

Lilly

Type II diabetes

Phase I

Previous slide

Next slide

Back to first slide

View graphic version